Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers human albumin serum under the Octapharma, Octapamma, and Octenor name for the treatment of premature infants, hypovolemia, hypoproteinemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, cardiopulmonary bypass, special types of hemodialysis, and plasma exchange. It also provides Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections. In addition, it is involved in the research, development, and sale of pharmaceutical products; provision of warehouse facilities for pharmaceutical products; research and manufacturing of aesthetic medicine; international trade activities; consultation services for medical and biological technology; market promotion; and medical beauty services. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited operates as a subsidiary of Risun Investments Limited.
